Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03296761

Enrollment

Registered

2017-09-28

Start date

2017-11-01

Completion date

2018-02-20

Last updated

2017-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS

Brief summary

To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its clinical significance.

Detailed description

70 patients who diagnosed as ARDS were included in this study. Then keep blood samples from these patients in the first day, the third day and the seventh day, detect ESM-1 level in plasma by ELISA. Record Severity of illness and survival status of every patient within 28 days. Objective to evaluate the correlation between the level of ESM-1 in plasma and the prognosis of the patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Patients admitted to ICU diagnosed of ARDS (Berlin definition）in 48h 2. Patients age between 18 years old and 80 years.

Exclusion criteria

： 1. Pregnant women, 2. Patients with malignant tumor, 3. Immunosuppression or immunocompromised patients.

Design outcomes

Primary

Measure	Time frame
mortality	28-day

Countries

China

Contacts

Primary ContactYuanyuan YU

220153911@seu.edu.cn15651680953

Backup ContactHaibo qiu

haiboq2000@163.com+862583262550

Outcome results